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Aims To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measur-




In 413 734 participants from UK Biobank, associations of serum Lp(a) with composite fatal/non-fatal CVD (n = 10 066
events), fatal CVD (n = 3247), coronary heart disease (CHD; n = 18 292), peripheral vascular disease (PVD; n = 2716), and
aortic stenosis (n = 901) were compared using Cox models. Median Lp(a) was 19.7 nmol/L (interquartile interval 7.6–
75.3 nmol/L). About 20.8% had Lp(a) values >100 nmol/L; 9.2% had values >175 nmol/L. After adjustment for classical risk
factors, 1 SD increment in log Lp(a) was associated with a hazard ratio for fatal/non-fatal CVD of 1.12 [95% confidence
interval (CI) 1.10–1.15]. Similar associations were observed with fatal CVD, CHD, PVD, and aortic stenosis. Adding Lp(a)
to a prediction model containing traditional CVD risk factors in a primary prevention group improved the C-index by
þ0.0017 (95% CI 0.0008–0.0026). In the whole cohort, Lp(a) above 100 nmol/L was associated with a population attribut-
able fraction (PAF) of 5.8% (95% CI 4.9–6.7%), and for Lp(a) above 175 nmol/L the PAF was 3.0% (2.4–3.6%). Assuming
causality and an achieved Lp(a) reduction of 80%, an ongoing trial to lower Lp(a) in patients with CVD and Lp(a) above
175 nmol/L may reduce CVD risk by 20.0% and CHD by 24.4%. Similar benefits were also modelled in the whole cohort,
regardless of baseline CVD.
...................................................................................................................................................................................................
Conclusion Population screening for elevated Lp(a) may help to predict CVD and target Lp(a) lowering drugs, if such drugs
prove efficacious, to those with markedly elevated levels.
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Lipoprotein (a) (Lp(a)) is a low-density lipoprotein (LDL) particle
made by the liver, comprised of both an apolipoprotein(a) and an
apolipoprotein B protein. Its structure is highly heterogeneous, but
levels of Lp(a) are 80–90% genetically determined and relatively sta-
ble across the life course.
Epidemiological evidence shows strong associations of circulating
Lp(a) with atherogenesis and consequent risk of cardiovascular disease
(CVD). For instance, in a recent meta-analysis of statin trial data, those
with Lp(a) concentrations above 50 mg/dL were at 35% higher risk of
incident CVD events [95% confidence interval (CI) 11–66%] com-
pared to those with Lp(a) <15 mg/dL (30 nmol/L) after adjusting for
confounders.1 Similar data have been reported in population studies.2,3
Furthermore, genetic data and basic science support the notion that
the association is causal.4,5 This has led to interest both in the potential
for Lp(a) to serve as a biomarker to enhance CVD risk prediction,6
and as a therapeutic target. Indeed, Lp(a) lowering drugs may be a vi-
able therapeutic option, with at least one drug moving to Phase 3 in
the Lp(a)HORIZON trial.7 Further, proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitors, which lower Lp(a) concentrations by
around 27%, may be particularly beneficial in reducing risk in patients
with previous CVD and substantially raised Lp(a).8,9
Currently, most guidelines and consensus statements do not advo-
cate widespread screening for elevated Lp(a) and suggest focused
measurement considering high Lp(a) as a risk enhancer.10–12 However,
the recently released ESC/EAS guidelines suggested a ‘one-off meas-
urement of Lp(a) may help to identify people with very high inherited
Lp(a) levels who may have a substantial lifetime risk of atherosclerotic
cardiovascular disease (ASCVD)’.13 Although Lp(a) is sometimes
measured in patients with suspected familial hypercholesterolaemia,14
it is currently not routinely measured in general practice.11 In addition,
there is conflicting advice on what constitutes a ‘high’ Lp(a) level.
Several guidelines and consensus statements advocate the 50 mg/dL
(125 nmol/L) cut-off10,11,15 as this corresponds to the 80th percentile
in one cohort study,16 but the 2016 Canadian Cardiovascular Society
Guidelines use 30 mg/dL on the basis of elevated CVD risk (75 nmol/
L).17 The Lp(a)HORIZON trial uses 70 mg/dL (175 nmol/L) as an in-
clusion criterion.7 The lack of data from a single large cohort with con-
sistent phenotyping is a significant limitation in interpreting the existing
literature, impacting our understanding of the prevalence of high Lp(a),
and its consequences for CVD risk.
UK Biobank is a large prospective population-based cohort study
carried out in the UK, with information on baseline biochemistry
measurements including routine lipids and Lp(a) measured in a cen-
tral laboratory. We aimed to use this resource to explore the shape
of the association of Lp(a) with a range of distinct CVD outcomes to
investigate the population attributable risk fraction for CVD that
might be explained by elevated Lp(a), and to predict what might be
the effect of novel Lp(a)-lowering therapies based on these data and
recent relevant trials.
Methods
UK Biobank was conducted across 22 assessment centres across the UK
between March 2006 and December 2010 and recruited 502 624
participants aged 37–73. A repeat visit was conducted between 2009 and
2013 for 20 345 individuals. Baseline biological measurements were
recorded and touch-screen questionnaires were administered according
to a standardized protocol.18,19 UK Biobank received ethical approval
from the North West Multi-Centre Research Ethics Committee (REC
reference: 11/NW/03820). All participants gave written informed con-
sent before enrolment in the study, which was conducted in accordance
with the principles of the Declaration of Helsinki.
For the present analysis, ethnicity was coded as White, South Asian,
Black, or mixed/other. Smoking status was categorized into never or for-
mer/current smoking. Systolic and diastolic blood pressure were meas-
ured at the baseline visit, preferentially using an automated measurement,
but using manual measurement where this was not available. Blood col-
lection sampling procedures for the study have been previously described
and validated.20 The definition of baseline diabetes included self-reported
type 1 or type 2 diabetes, those with a primary or secondary hospital
diagnoses relating to diabetes at baseline (ICD-10 codes E10–E14.9), and
those who reported using diabetes medications. Statin (categorized to in-
clude other cholesterol lowering medications) and blood pressure medi-
cation use were also recorded from self-report. Baseline CVD was
defined as self-reported myocardial infarction, stroke, or transient ischae-
mic attack.
Biochemistry measures were performed at a dedicated central labora-
tory on around 480 000 baseline samples between 2014 and 2017.
During the project, the UK Biobank laboratories were successfully exter-
nally audited against the ISO 17025:2005 standard. Assays included serum
total cholesterol and high-density lipoprotein (HDL) cholesterol
(Beckman Coulter, UK on an AU5800 platform) and Lp(a) (Randox
Bioscience, UK on an AU5800 platform) and all were run using internal
controls and an external quality assurance scheme. Data were adjusted
by UK Biobank centrally before release to adjust for pre-analytical varia-
bles. For Lp(a), low-, medium-, and high-quality control materials ran with
coefficients of variation of <_6.1%. Further details of these measurements
can be found in the UK Biobank online showcase and protocol (http://
www.ukbiobank.ac.uk, accessed 9 September 2020). The Randox Lp(a)
assay is calibrated in nmol/L, reflecting the concentration of particles ra-
ther than the mass of particles and is traceable to the WHO/IFCC refer-
ence material. The minimum reported concentration of Lp(a) was
3.8 nmol/L and the maximum was 189 nmol/L; participants who had levels
below the lower level (n = 48 360) were coded as having an Lp(a) con-
centration of 2.88 nmol/L, and above the upper level (n = 34 195) coded
as 250 nmol/L for continuous analyses.
Date and cause of death were obtained from death certificates held by
the National Health Service (NHS) Information Centre for participants
from England and Wales and the NHS Central Register Scotland for par-
ticipants from Scotland. Only primary causes of death listed on the death
certificate were included in this analysis. Non-fatal outcomes were ascer-
tained by linkage of participant study data to Hospital Episode Statistics
from the National Health Service. The primary outcome of interest was
ASCVD; this and secondary outcomes are defined in Supplementary ma-
terial online.
End of follow-up for each participant was recorded as the date of
death or the date of end of follow-up for the assessment centre attended,
whichever came first. The period at risk of each participant began on the
date of their assessment.
Statistical analyses
The association of continuous log-transformed Lp(a) with other lipid vari-
ables was tested using Pearson correlation coefficients. Lp(a) was ana-
lysed using a number of different models, reflecting existing uncertainty
regarding cut-offs for ‘abnormal’ levels. Lp(a) was categorized into
































































































multiple distinct categorical variables, with upper cut-offs at 20 nmol/L
and 100 nmol/L or 125 nmol/L or 150 nmol/L or 175 nmol/L. Sex and
ethnicity-specific centiles (50th, 75th, 80th, 90th, and 95th centiles) for
Lp(a) were also developed, using binomial exact CIs to yield 95% CIs for
the centiles. The sex and ethnicity-specific 80th centile were chosen to
create a binary ‘high’ category for Lp(a). Log-transformed Lp(a) was also
analysed as a continuous variable. Classical risk factors were expressed as
mean (standard deviation) if symmetrically distributed, median (interquar-
tile range) if skewed, and number (%) if categorical. The distribution of
classical risk factors by categories of outcome or exposure of interest
was assessed using unpaired two-tail t-tests, a Wilcoxon rank-sum, or a
v2 test, respectively.
Prospectively, the cohort was analysed as a whole cohort and was also
stratified as a primary prevention cohort (participants without baseline
CVD and not taking a statin) and as a high-risk cohort (participants with
baseline CVD and/or taking a statin). We assessed agreement between
baseline and repeated Lp(a) measurements in those with available data
using Lin’s Correlation coefficient and the mean difference in measure-
ment, along with 95% limits of agreement, and using the coefficient of
variation across the two visits.
Rates of the primary composite CVD outcome were investigated in
unadjusted models, splitting the cohort by the specified Lp(a) categories.
Associations of continuous and categorical Lp(a) with outcomes of inter-
est were investigated using Cox-proportional hazard models in the whole
cohort adjusting for classical risk factors. The ability of Lp(a) to improve
prediction of CVD was tested by assessing improvement over a base
model containing all elements from the Pooled Cohort Equation
(Supplementary material online).
Population attributable fractions in the exposed, with 95% CIs,
were estimated using two adjusted Cox models and the punafcc
post-estimate command in STATA. The model added Lp(a) at a num-
ber of binary cut-offs and was designed to estimate the causal effect
of ‘elevated’ Lp(a) in the whole cohort for each outcome. The second
model, intended to represent anticipated benefit of therapeutic inter-
vention in those with elevated Lp(a), added Lp(a) as a four-category
variable with concentration >175 nmol/L (representing the
Lp(a)HORIZON trial recruitment criterion7), 40–175 nmol/L, 30–
40 nmol/L (the estimated attained Lp(a) assuming an 80% reduction
on-treatment21), and <30 nmol/L. This model was then used to test
the estimated proportional reduction in CVD events among those
with Lp(a) >175 nmol/L when concentration was lowered to the 30–
40 nmol/L range. The model was run specifically in those with baseline
CVD and in the whole cohort.




Of 502 624 people included in the study, complete data on covari-
ates, including Lp(a) were available in 413 734 participants. Median
Lp(a) in the cohort was 19.7 nmol/L (interquartile interval 7.6–
75.3 nmol/L). In participants without baseline CVD and not taking a
statin (n = 340 339) median Lp(a) was 19.1 nmol/L (interquartile
interval 7.6–70.5 nmol/L). The 80th centile in the whole cohort was
104.5 nmol/L (95% CI 103.8–105.3). In the whole cohort, 85 932
(20.8%) had Lp(a) above 100 nmol/L, 68 603 (16.6%) above
125 nmol/L, 52 159 (12.6%) above 150 nmol/L, and 38 111 (9.2%)
above 175 nmol/L. Sex and ethnicity-specific cut-offs show that
women and participants with black ethnicity had higher Lp(a) concen-
trations (Figure 1).
Lipoprotein (a) had weak positive associations with total choles-
terol (r = 0.11), HDL cholesterol (r = 0.04), and LDL cholesterol
(r = 0.12) (P for all < 0.0001). These associations were only nominally
stronger in the population who did not report taking statins (r = 0.14,
0.05, 0.16, respectively). Participants with elevated Lp(a) were gener-
ally slightly older, had slightly higher systolic blood pressure and total
cholesterol and were more likely to have baseline CVD (Table 1).
Repeated measures of lipoprotein (a)
Fourteen thousand, two hundred, and forty-eight participants from
the baseline cohort had repeated measures of Lp(a) available. At the
follow-up visit, Lp(a) was 2.9 nmol/L higher, the 95% limits of agree-
ment for Lp(a) between the two visits were -37.5, 43.3 nmol/L, and
the median coefficient of variation was 12.6% (interquartile range
3.8–24.7%). The concordance coefficient was 0.958 (95% CI 0.957–
0.959) (Supplementary material online, Figure S1).
Univariable association of lipoprotein (a)
with outcomes
Median follow-up time for the composite CVD outcome was
8.9 years (interquartile range 8.2–9.5) in the whole cohort. The com-
posite CVD outcome occurred in 10 066 participants (2.4%), and
fatal CVD occurred in 3247 participants (0.8%) in the whole cohort.
The composite CVD outcome occurred in 6125 participants (1.8%),
and fatal CVD occurred in 1627 participants (0.5%) in the subgroup
without baseline CVD and not taking a statin.
Baseline Lp(a) was higher among the participants who went on
to experience the composite CVD outcome and the fatal CVD
outcome (Supplementary material online, Table S1). Lp(a) was
also higher among those who went on to experience coronary
heart disease (CHD), peripheral vascular disease (PVD), or aortic
valve stenosis but was not higher among those who went on to
experience ischaemic stroke, heart failure (Supplementary material
online, Table S1).
Multivariable association of lipoprotein
(a) with outcomes
In the whole cohort, there was an independent association of 1 SD
increase in log Lp(a) with the primary composite CVD outcome [haz-
ard ratio (HR) 1.12 (95% CI 1.10–1.15)] after adjusting for classical
risk factors statin use and baseline CVD. In the whole cohort, an
18 nmol/L (10 mg/dL) increase in Lp(a) was associated with an
increased risk of CVD and CHD: HR 1.029 (95% CI 1.024–1.033)
and HR 1.035 (95% CI 1.031–1.038), respectively.
For the primary outcome of CVD there was no interaction of
Lp(a) with age (above or below the median of 57 years) (P = 0.16),
sex (P = 0.27), ethnicity (P > 0.23 for each ethnic group compared to
white), baseline CVD (P = 0.24), baseline diabetes (P = 0.17), statin
use (P = 0.61), total cholesterol (above or below 8.0 mmol/L cut-off)
(P = 0.38), or LDL cholesterol (above or below 2.5 mmol/L cut-off)
(P = 0.72). However, there was a borderline interaction of log Lp(a)
with LDL cholesterol using a cut-off of 3.5 mmol/L (P for interaction
0.055). In this model each standard deviation increase in log Lp(a) had
an HR of 1.11 (95% CI 1.08–1.13) in the group with LDL cholesterol






















<3.5 mmol/L and an HR of 1.15 (95% CI 1.12–1.18) in the group with
LDL cholesterol >_3.5 mmol/L.
Data were split into the primary prevention cohort and the high-
risk cohort to further explore associations with outcomes. Among
the primary prevention group not taking a statin, after adjusting for
classical risk factors, the shape of the association of Lp(a) with com-
posite CVD, fatal CVD, CHD, and aortic valve stenosis was positive
and broadly linear (Figure 2). There was also a positive association
with PVD, but no evidence of an association with stroke, or heart fail-
ure (Figure 2).
Using continuous and multiple different categorical models of
Lp(a) there was a positive association with composite primary CVD
outcome (Table 2). Lp(a) as a continuous and categorical variable
was also associated with fatal CVD, CHD, PVD, and aortic valve
stenosis as well as demonstrating a borderline association with is-
chaemic stroke after adjusting for classical risk factors, in both the
Figure 1 Centiles of lipoprotein (a), along with 95% confidence intervals, by sex and ethnicity in the whole cohort. Red denotes white ethnicity,
green denotes black ethnicity, blue denotes South Asian, and purple denotes other or mixed ethnicity. Lp(a), lipoprotein (a); nmol/L, nanomoles per
litre.


















































..primary prevention cohort and the high-risk cohort (Supplementary
material online, Table S2). The association with heart failure was
weak. In terms of strength of the point estimates, the association of
Lp(a) with aortic valve stenosis was strong and consistent; those
with Lp(a) >_175 nmol/L were at 85% increased risk of both out-
comes in both the primary prevention cohort and the high-risk co-
hort (Supplementary material online, Table S2).
Lipoprotein (a) and prediction of
cardiovascular disease
Prediction of incident CVD was specifically explored in the primary
prevention cohort. In a model of CVD prediction based on pooled
cohort equation risk factors, classical risk factors yielded a C-index
of 0.7459 (95% CI 0.7402–0.7517). Addition of Lp(a) as a continu-
ous variable to these risk factors increased the C-index by
þ0.0017 (95% CI 0.0008–0.0026) (Table 3). On addition of Lp(a)
to the model, the improvement in the categorical net reclassifica-
tion index was þ0.0112% (95% CI þ0.0039 to þ0.0184) and
most of the improvement was due to upward classification of risk
among cases (Table 3). Similar improvements in prediction were
obtained when Lp(a) was added as a categorical variable, with no
clear advantage of one model over another (Table 3). There was
a more sizeable improvement in reclassification among the
intermediate-risk group at 5–7.49% 10-year risk (n = 16 292); on
addition of continuous Lp(a), the overall net reclassification index
in this intermediate-risk group was þ0.0721 (95% CI þ0.0323,
þ0.1107).
Population attributable fraction of
lipoprotein (a)
In the whole cohort, an Lp(a) above 100 nmol/L accounted for
5.8% (95% CI 4.9–6.7%) of the composite CVD outcome
(Figure 3). Moving the threshold for ‘high’ Lp(a) to higher cut-
offs resulted in somewhat lower, but still substantial, attributable
fractions due to reduced prevalence of the higher cut-offs
(Figure 3). The overall PAF lowered to 3.0% (95% CI 2.4–3.6%)
for a cut-off of Lp(a) above 175 nmol/L. The proportion of
CVD attributable due to any Lp(a) >3.8 nmol/L in the whole
cohort was 8.8% (95% CI 7.6–10.0%); this is the reduction in
risk expected if the whole cohort had Lp(a) of 3.8 nmol/L
(Supplementary material online, Figure S2).
Expected benefit of lipoprotein (a)
reduction
We then specifically modelled the scenario in the ongoing Phase 3
trial of an Lp(a) lowering agent. First, among all participants regardless
of baseline CVD status (n = 413 734), the CVD event rate was 2.80
(95% CI 2.74–2.85) per 1000 person-years. Among those with an
Lp(a) above 175 nmol/L (n = 38 111), reducing Lp(a) by80% so that
participants have Lp(a) 30–40 nmol/L range, results in an estimated
risk reduction of 23.1% (95% CI 14.9–30.5%). For prevention of
CHD, the same Lp(a) reduction was estimated to result in a 28.3%
decrease in risk (95% CI 22.8–33.4%). In a sensitivity analysis remov-
ing individuals with Lp(a) above the reported measurable range
.................... ........................ ....................
....................................................................................................................................................................................................................
Table 1 Association of categories of lipoprotein (a) with classical risk factors for cardiovascular disease at baseline
(n 5 413 724)
Lp(a) Lp(a) Lp(a) P-value
for trend
<20 nmol/L 20–99.9 nmol/L 100 nmol/L
n 5 207 908 n 5 119 894 n 5 85 932
Age (years) 56.3 ± 8.2 56.7 ± 8.1 56.9 ± 8.0 <0.001
Male sex (%) 101 214 (48.7%) 52 542 (43.8%) 37 403 (43.5%) <0.001
Ethnicity (%)
White 201 070 (96.7%) 109 952 (91.7%) 80 955 (94.2%) <0.001
Black 717 (0.3%) 3327 (2.8%) 2404 (2.8%)
South Asian 2427 (1.2%) 2931 (2.4%) 1064 (1.2%)
Other 3694 (1.8%) 3684 (3.1%) 1509 (1.8%)
Systolic blood pressure
(mmHg)
137.9 ± 18.6 137.7 ± 18.7 138.4 ± 18.7 <0.001
Diastolic blood pressure
(mmHg)
82.3 ± 10.2 82.2 ± 10.1 82.4 ± 10.1 0.008
Ever smoker (%) 22 089 (10.6%) 12 761 (10.6%) 8995 (10.5%) 0.38
Total cholesterol (mmol/L) 5.59 (1.12) 5.75 (1.15) 5.86 (1.18) <0.001
HDL cholesterol (mmol/L) 1.44 (0.39) 1.45 (0.38) 1.48 (0.38) <0.001
Baseline diabetes (%) 11 463 (5.5%) 5764 (4.8%) 4453 (5.2%) <0.001
Baseline CVD (%) 11 133 (5.4%) 6900 (5.8%) 6614 (7.7%) <0.001
Statin use (%) 31 230 (15.0%) 18 620 (15.5%) 17 376 (20.2%) <0.001
BP medication (%) 42 159 (20.3%) 24 578 (20.5%) 19 571 (22.8%) <0.001
BP, blood pressure; CVD, cardiovascular disease; HDL, high-density lipoproteins; mmHg, millimetres of mercury; mmol/L, millimoles per litre; nmol/L, nanomoles per litre.
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Figure 2 Association of Lp(a) with outcomes after adjusting for classical risk factors among participants without baseline cardiovascular disease and
not taking a statin. Referent (hazard ratio = 1.0) at 19 nmol/L. AHA, American Heart Association; HF, heart failure; HR, hazard ratio; Lp(a), lipoprotein
(a); nmol/L: nanomoles per litre; PVD, peripheral vascular disease.




















































(>189 nmol/L), reduction of Lp(a) in the range of 175–189 nmol/L to
30–40 nmol/L results in an estimated CVD risk reduction of 16.3%
(95% CI 2.5–28.2%).
Specifically investigating participants with baseline CVD
(n = 24 647) the CVD event rate was 11.7 (95% CI 11.3–12.2) per
1000 person years. Among those with an Lp(a) above 175 nmol/L
(n = 3568), similar Lp(a) reductions are estimated to reduce CVD
risk by 20.0% (95% CI 2.1–34.6%) and CHD risk by 24.4% (95% CI
13.5–33.9%).
Discussion
In this large cohort of over 400 000 individuals, a high proportion of the
UK Biobank cohort had what might conventionally be called high Lp(a)
levels; 20.8% above 100 nmol/L and 9.2% above 175 nmol/L. Intra-
individual concordance in Lp(a) levels across visits years apart was high.
We noted a broadly linear relationship of Lp(a) with composite fatal or
nonfatal CVD, fatal CVD, and fatal or non-fatal CHD, PVD, and aortic
stenosis with associations largely unaffected by other risk factors.
Therefore, population attributable fractions for Lp(a) were sizable.
Further, we estimate that targeting Lp(a) lowering therapy in ongoing
trials to those with Lp(a) concentrations above 175 nmol/L would re-
duce CVD incidence by around 20% (regardless of baseline CVD sta-
tus). This extends estimates22 from smaller studies to a current
ongoing trial. Collectively, our results seem to justify the recent ESC/
EAS guidelines13 suggesting consideration for at least a one-time Lp(a)
measurement in all people being screened for CVD risk.
Genetic data suggest large reductions in Lp(a) are required to
show clinical benefit, although there is some disagreement as to the
extent of the reduction required.4,5 The study of Burgess et al.4 esti-
mated that a 10 mg/dL decrease in Lp(a) (18 nmol/L) would cause a
5.8% decrease in odds of CHD, whereas Lamina and Kronenberg5
estimated it would be an 8.8% reduction in odds. Our estimate that
an 18 nmol/L increase in Lp(a) would be associated with a 3.5%
increased CHD risk is therefore somewhat more conservative than
the genetic data. Mendelian randomization studies may offer better
causal insights than observational studies for many traits, although
pleiotropy and lifelong exposure to elevated levels of Lp(a) may also
have an impact on estimates.23 Our more conservative estimate, if
correct, would imply a requirement for greater Lp(a) reduction to
achieve reduced CVD risk. Despite this, recent Phase 2 trial data
show that the drug AKCEA-APO(a)-LRx (also called TQJ230)
reduces Lp(a) substantially, with 80–90% reductions in patients with
established CVD and high Lp(a) levels, depending on dosing.21,24 This
antisense oligonucleotide inhibits the production of apolipopro-
tein(a), thereby reducing Lp(a). Phase 3 outcome trials are underway7
and specifically target those with elevated Lp(a). Furthermore, there
is also emerging evidence that proprotein convertase subtilisin/kexin
type 9 inhibitors lower Lp(a) independent of LDL cholesterol reduc-
tion, and this reduction contributes to CVD event reduction9 and
lowering of PVD risk.25,26 These findings provide a currently licensed
drug to help lower Lp(a) by a modest amount.
Our data suggest that a drug that prevents CVD through Lp(a)
lowering may also have benefits for individual components of the
CVD composite, and for PVD outcomes, as well as aortic stenosis.
................................................................ ................................................................
....................................................................................................................................................................................................................
Table 2 Association of Lp(a) (hazard ratio and 95% CI) as a continuous variable (per 1 SD increase in log Lp(a)) and as
a categorical variable with the primary composite CVD outcome after adjusting for classical risk factorsa
Lp(a) conc. Primary prevention cohort High-risk cohortb
N (n events) HR (95% CI) N (n events) HR (95% CI)
Per 1 SD 340 339 (6125) 1.13 (1.10–1.16) 73 395 (3941) 1.11 (1.08–1.14)
<20 nmol/L 173 639 (2857) Ref 34 269 (1689) Ref
20–99.9 nmol/L 99 499 (1802) 1.11 (1.05–1.18) 20 395 (1086) 1.11 (1.03–1.20)
>_100 nmol/L 67 201 (1466) 1.37 (1.28–1.46) 18 731 (1166) 1.30 (1.21–1.41)
<20 nmol/L 173 639 (2857) Ref 34 269 (1689) Ref
20–124.9 nmol/L 114 093 (2086) 1.13 (1.06–1.19) 23 130 (1241) 1.11 (1.03–1.20)
>_125 nmol/L 52 607 (1182) 1.40 (1.31–1.50) 15 996 (1011) 1.34 (1.24–1.45)
<20 nmol/L 173 639 (2857) Ref 34 269 (1689) Ref
20–149.9.9 nmol/L 127 636 (2371) 1.15 (1.09–1.21) 26 031 (1428) 1.13 (1.06–1.22)
>_150 nmol/L 39 064 (897) 1.43 (1.33–1.55) 13 095 (824) 1.35 (1.24–1.47)
<20 nmol/L 173 639 (2857) Ref 34 269 (1689) Ref
20–174.9 nmol/L 138 836 (2626) 1.17 (1.11–1.23) 28 879 (1608) 1.15 (1.08–1.23)
>_175 nmol/L 27 864 (642) 1.44 (1.32–1.58) 10 247 (644) 1.36 (1.24–1.49)
Below the sex and ethni-
city-specific 80th centile
275 892 (4672) Ref 54 886 (2768) Ref
Above the sex and ethni-
city-specific 80th centile
64 447 (1453) 1.31 (1.24–1.39) 18 509 (1173) 1.26 (1.18–1.35)
CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard ratio; Lp(a), lipoprotein (a); nmol/L, nanomoles per litre; SD, standard deviation.
aAge, sex, total cholesterol, HDL cholesterol, ethnicity, smoking, systolic blood pressure, blood pressure medications, and baseline diabetes.
bParticipants with baseline CVD or taking a statin; additionally, adjusted for baseline CVD and statin use.



























































Our models suggest potential benefit in both primary and secondary
prevention. Although Lp(a) only adds moderate information to risk
discrimination metrics and is more expensive than traditional lipid
measurements,27 the fact that the marker is (i) causal, (ii) largely or-
thogonal to other risk factors, (iii) stable across life course, (iv) has a
substantial population attributable fraction, and (v) may help guide
therapy allocation, enhances arguments that measurement of Lp(a)
should become more common in the evaluation of CVD risk.
Notably, the reported improvement in C-statistics with Lp(a) was
around four times higher than previously reported for C-reactive
protein.28 In particular, we show that incorporation of Lp(a) into risk
scores targeted at intermediate-risk groups would lead to changes in
a greater proportion of treatment decisions than measurement in the
whole general population. This may be a method to tie-break treat-
ment decisions in a targeted manner, in line with current US guide-
lines. There are a range of suggested cut-offs for Lp(a) in clinical
practice.10,15,29 The data reported here are consistent with the ap-
proach of the Lp(a)HORIZON trial in identifying >175 nmol/L as a
risk marker. The results of this and other trials should help inform on
the most cost-effective cut-offs used in future for clinical care.
The ethnicity-specific centiles we report confirm and extend
observations in other cohorts, most noticeably higher Lp(a) in black
people.30 We would expect a higher PAF for CVD outcomes in black
ethnicities due to higher prevalence of the exposure, but low num-
bers of black participants restrict our ability to formally test this hy-
pothesis in this cohort. Overall, we note no strong interaction of
Lp(a) with demographics or other risk factors suggesting that Lp(a) is
similarly associated with risk in different subgroups. Previous work in
primary prevention cohorts from EPIC-Norfolk and the Copenhagen
City Heart Study (n = 16 654) has suggested that the association be-
tween elevated Lp(a) (>80th percentile) and CVD events is attenu-
ated at LDL cholesterol levels below 2.5 mmol/L.31 Likewise, data
from the Women’s Health Study and JUPITER trials reported stron-
ger associations of Lp(a) above 50 mg/dL with CVD risk at total chol-
esterol levels above 5.7 mmol/L.3 We report borderline evidence
that continuous Lp(a) may have a slightly weaker risk association in
people with directly measured LDL cholesterol <3.5 mmol/L, but this
is not evident at a cut-off of 2.5 mmol/L, and the association with
....................................................................................................................................................................................................................
Table 3 Improvement in prediction of cardiovascular disease among participants in the primary prevention cohort












Classical risk factorsa 0.7459
(0.7402–0.7517)
Classical risk factors þ continuous log
Lp(a)
þ0.0017 þ0.0112 0.0118 -0.0007
(0.0008–0.0026) (þ0.0039, þ0.0184) (þ0.0046, þ0.0190) (-0.0012, -0.0002)
Classical risk factors þ categorical
Lp(a) at <20, 20–99.9, and
>100 nmol/L
þ0.0018 þ0.0108 0.0118 -0.0009
(0.0009–0.0026) (þ0.0040, þ0.0175) (þ0.0050, þ0.0184) (-0.0014, -0.0004)
Classical risk factors þ categorical
Lp(a) at <20, 20–149.9, and
>150 nmol/L
þ0.0016 þ0.0135 0.0144 -0.0009
(0.0007–0.0024) (þ0.0063, þ0.0203) (þ0.0063, þ0.0203) (-0.0014, -0.0004)
Classical risk factors þ binary Lp(a) at
sex and ethnicity-specific 80th
percentile
þ0.0015 þ0.0111 0.0115 -0.0004
(0.0007–0.0023) (þ0.0045, þ0.0180) (þ0.0050, þ0.0184) (-0.0009, -0.0001)
CVD, cardiovascular disease; HDL, high-density lipoprotein; Lp(a), lipoprotein (a); nmol/L, nanomoles per litre; NRI, net reclassification index.
aAge, sex, total cholesterol, HDL cholesterol, ethnicity, smoking, systolic blood pressure, blood pressure medications, and baseline diabetes.
Figure 3 Population attributable fractions (with 95% confidence
intervals) of lipoprotein (a) in the whole cohort, at a range of cut-
offs, for each outcome of interest. ACC, American College of
Cardiology; AHA, American Heart Association; CHD, coronary
heart disease; CVD, cardiovascular disease; HF, heart failure; Lp(a),
lipoprotein (a); nmol/L: nanomoles per litre; PVD, peripheral vascu-
lar disease; SCORE, Systematic Coronary Risk Estimation.





























































































.CVD remains clinically relevant and statistically significant in both
LDL cholesterol groups.
The PAFs we report for Lp(a) may usefully be put in context of
estimates of PAFs for other risk factors. The ARIC study reported
PAFs at examination four (among white participants) of 21% for
hypertension, 13% for diabetes, 10% for hypercholesterolaemia, and
12% for smoking.32 Similarly, in the Emerging Risk Factors
Collaboration, the PAF for diabetes in vascular death has been esti-
mated at 11% (assuming a 10% diabetes prevalence).33 In terms of
CVD risk prediction, our data are also broadly in line with the
Emerging Risk Factors Collaboration (ERFC), where data from
165 544 participants in 37 prospective studies showed Lp(a)
improved the C-index by þ0.0016 (95% CI 0.0009–0.0023),34 lend-
ing strong external validity to these new reported findings. It is also in
agreement with data from other large cohort studies.35–38 Our data
extend these findings in a large cohort with substantial power, using a
single methodologically strong Lp(a) measurement, where we also
estimated the PAF for a range of CVD outcomes independently due
to Lp(a) elevation.
The strengths of our study include the large cohort size at an
age-relevant to CVD risk scoring and biochemistry assays per-
formed in a single dedicated central laboratory. We were also
able to extensively adjust our models for classical risk factors and
separately analysed participants already on statins as well as those
with previous CVD. We were also able to investigate at other
cardiovascular outcomes. Potential limitations include the relatively
low average CVD risk of participants, although risk prediction
models performed broadly in line with expectations. UK Biobank
is not representative of the whole UK population,35 and while this
is generally not a concern in investigating risk associations39 it will
have an impact on calculated population attributable fractions.
The population attributable fractions we observe here cannot be
taken as representative of the UK population as a whole.
However, due to the under-representation of black people in UK
Biobank, it may be that our estimates are conservative. In add-
ition, the 80th centile we report here of 105 nmol/L corresponds
broadly to previously reported 80th centiles in 3000 men and
3000 women from the Copenhagen General Population Study
(50 mg/dL).11 The upper reported Lp(a) concentration in UK
Biobank is 189 nmol/L, limiting our ability to investigate associa-
tions higher than this concentration. Finally, UK biobank is a pri-
marily primary prevention low-risk population, and extrapolation
to secondary prevention settings and modelled therapeutic bene-
fits (such as the Lp(a)HORIZON trial) must be interpreted with
caution. However, the secondary prevention group is still sizeable
and has appreciably higher CVD events rates than the cohort as a
whole, and we observe no evidence of interaction of the PAF for
Lp(a) lowering by baseline CVD status. Our estimates of
expected therapy effects among the exposed (Lp(a) above
175 nmol/L) should be robust to differences in representativeness,
since we only consider those with high Lp(a) as exposed.
In conclusion, in this, the largest single prospective study of Lp(a)
levels, our findings add strong support for recent guideline recom-
mended one-time measurement of Lp(a) in cardiovascular risk as-
sessment to identify a large proportion with markedly elevated levels
sufficient to contribute to atherothrombotic risk. Our work also
provides support to the ongoing programmes to develop efficacious
Lp(a) lowering drugs.
Supplementary material
Supplementary material is available at European Journal of Preventive
Cardiology online.
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